IC
RARE icon

Ikarian Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Ikarian Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.1M Buy
482,571
+469,900
+3,708% +$10.6M 0.82% 34
2025
Q4 		$291K Buy
+12,671
New +$417K 0.02% 148
2025
Q2 		– Sell
-216,989
Closed -$7.82M – 178
2025
Q1 		$7.86M Buy
216,989
+38,000
+21% +$1.58M 0.97% 18
2024
Q4 		$7.53M Sell
178,989
-11
-0% -$546 1.02% 24
2024
Q3 		$9.94M Buy
+179,000
New +$9.12M 1.39% 19
2023
Q4 		– Sell
-174,945
Closed -$6.24M – 167
2023
Q3 		$6.24M Buy
174,945
+53,287
+44% +$2.11M 0.75% 37
2023
Q2 		$5.61M Buy
+121,658
New +$5.64M 0.89% 36
2020
Q3 		– Sell
-2,313
Closed -$181K – 205
2020
Q2 		$181K Sell
2,313
-11,939
-84% -$790K 0.01% 150
2020
Q1 		$633K Sell
14,252
-35,748
-71% -$1.86M 0.05% 128
2019
Q4 		$2.14M Buy
+50,000
New +$2.06M 0.35% 63

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Ikarian Capital's RARE Position: Q1 2026 in Review

Ikarian Capital increased its Ultragenyx Pharmaceutical (RARE) stake by 3,708% in Q1 2026, buying an estimated $10.6M and bringing the position to 482,571 shares worth $10.1M. The position accounts for 0.82% of the portfolio, ranked #34.

Ikarian Capital first reported a position in RARE in Q4 2019 and has held it in 10 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Ikarian Capital held 482,571 shares of Ultragenyx Pharmaceutical worth $10.1M as of Q1 2026.
  • Ikarian Capital bought 469,900 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $10.6M.
  • Ultragenyx Pharmaceutical made up 0.82% of Ikarian Capital's portfolio in Q1 2026, its #34 holding.
  • Ikarian Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and has held it in 10 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.